Seeing Is Believing
Currently out of the existing stock ratings of Cory Kasimov, 31 are a HOLD (31%), 66 are a BUY (66%), 3 are a SELL (3%).
Analyst Cory Kasimov works with a stock forecast success ratio of 65.23% fulfilled within 294.24 days on average. Previously, Cory Kasimov worked at JPMORGAN.
Cory Kasimov’s has documented 221 price targets and ratings displayed on 25 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on RARE, Ultragenyx at 27-Feb-2024.
Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
25
$8.41 (50.69%)
29
1 months 1 days ago
5/8 (62.5%)
$7.16 (40.13%)
26
Buy
30
$13.41 (80.83%)
40
1 months 13 days ago
16/19 (84.21%)
$10.44 (53.37%)
184
Buy
39
$22.41 (135.08%)
40
1 months 29 days ago
6/10 (60%)
$15.25 (64.21%)
94
Buy
33
$16.41 (98.92%)
33
1 months 29 days ago
8/19 (42.11%)
$9.25 (38.95%)
119
Buy
36
$19.41 (117.00%)
1 months 29 days ago
0/1 (0%)
$12.25 (51.58%)
Which stock is Cory Kasimov is most bullish on?
What Year was the first public recommendation made by Cory Kasimov?